Many preclinical assays and models are simplified biological systems designed to address specific and isolated questions. However, the ability of these systems to predict the clinical response in human patients remains limited and unreliable. There is a critical need to study metabolic disease in relevant tissue and in vivo systems.
Crown Bioscience leverages its extensive collaboration/network with diabetes clinics and research hospitals to collect well-annotated patient samples for a better understanding of the disease. We also leverage our unique collection of monkeys with spontaneous type II diabetes to study the disease in its most specific aspects in order to provide the critical pieces bridging the bench to the clinics.
- D*BankTM : a collection of tissues from patients with type II diabetes and from diabetic monkeys. Each tissue sample has detailed clinical annotations in order to provide the appropriate clinical context for the testing of genes, proteins, and pathways.
- D*BaseTM : Annotation database for tissues in the DBankTM collection, such as clinical and diagnostic information, and whole genome expression profiling data.
•
Target discovery and validation